[Berry Genomics 2025 Semi-Annual Performance Forecast Interpretation](index=1&type=section&id=%E8%B4%9D%E7%91%9E%E5%9F%BA%E5%9B%A02025%E5%B9%B4%E5%8D%8A%E5%B9%B4%E5%BA%A6%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A) This report interprets Berry Genomics' 2025 semi-annual performance forecast, detailing core financial projections, reasons for performance changes, and audit-related disclosures [Core Performance Forecast Data](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E6%83%85%E5%86%B5) The company anticipates a loss for the first half of 2025, with net profit attributable to shareholders projected to be a loss of RMB 22 million to RMB 33 million, a shift from a profit of RMB 9.2628 million in the same period last year Performance Forecast Summary | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders of Listed Company** | Loss: 22.00 - 33.00 million RMB | Profit: 9.2628 million RMB | | **Net Profit Excluding Non-Recurring Gains/Losses** | Loss: 24.00 - 35.00 million RMB | Profit: 9.49 million RMB | | **Basic Earnings Per Share** | Loss: 0.0622 - 0.0933 RMB/share | Profit: 0.0262 RMB/share | [Analysis of Performance Changes](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) The decline in performance is primarily attributed to external market conditions and internal strategic investments, including increased R&D and domestic substitution efforts, partially offset by non-recurring income - Company's operating revenue and profitability decreased year-on-year due to industry cyclicality and intensified market competition[4](index=4&type=chunk) - The company increased R&D investment, with its GENOisi intelligent agent project reaching cooperation intentions with multiple hospitals, while steadily advancing domestic substitution transformation, which is expected to improve future cost structure[4](index=4&type=chunk) - During the reporting period, the company recorded approximately **RMB 2 million** in non-recurring income, primarily from the disposal of Prenetics shares[4](index=4&type=chunk) [Audit and Risk Disclosure](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8E%E4%BC%9A%E8%AE%A1%E5%B8%88%E4%BA%8B%E5%8A%A1%E6%89%80%E6%B2%9F%E9%80%9A%E6%83%85%E5%86%B5%20%26%20%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The company emphasizes that this performance forecast data is a preliminary estimate by the finance department and has not been audited, with final data subject to the official semi-annual report - This performance forecast data is a preliminary estimate by the company's finance department and has not been audited by an auditing firm[3](index=3&type=chunk)[5](index=5&type=chunk) - The company has pre-communicated the performance forecast with the accounting firm, and there are no significant disagreements[3](index=3&type=chunk)

贝瑞基因（000710）公告，预计2025年上半年净利润亏损2200万元-3300万元，上年同期盈利926.28万 元。 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-034 成都市贝瑞和康基因技术股份有限公司 二、被担保人基本情况 1、名称：北京贝瑞和康生物技术有限公司 8、经营范围：一般项目：技术服务、技术开发、技术咨询、技术交流、技 术转让、技术推广；信息技术咨询服务；软件开发；健康咨询服务（不含诊疗 服务）；仪器仪表销售；第一类医疗器械销售；化工产品销售（不含许可类化 1 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保审批情况概述 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因""公司"） 于 2025 年 6 月 4 日召开第十届董事会第十五次会议审议通过了《关于为全资子 公司提供担保的议案》。公司之全资子公司北京贝瑞和康生物技术有限公司 （以下简称"北京贝瑞"）向中国银行股份有限公司北京首都机场支行（以下 简称"中行首都机场支行"）申请综合授信 3,000 万元，授信期限 1 年。公司 拟为北京贝瑞使用上述授信所形成的债务提供连带责任保证担保。具体内容详 见公司于 2025 年 6 月 6 日在巨 ...

Core Viewpoint - The third-party medical testing industry in China has experienced significant growth, particularly during the pandemic, with a market size reaching 630.5 billion yuan in 2022, but is expected to return to pre-pandemic levels in 2023 and stabilize around 388.8 billion yuan in 2024 [1][6]. Group 1: Industry Definition and Business Model - Medical testing is a discipline that utilizes modern physical and chemical methods for clinical diagnosis and treatment [2]. - Independent clinical laboratories (ICLs), also known as third-party medical laboratories, operate independently of hospitals and are licensed by health authorities to provide clinical testing and pathology services [2]. Group 2: Current Development Status - The ICL industry in China began in the 1980s and has become an essential part of the healthcare system due to increasing demand and favorable policies [4]. - The number of ICLs has grown from fewer than 70 in 2009 to an estimated 2,800 by 2024, with projections of reaching 2,845 by 2025 [4]. Group 3: Market Size and Growth Projections - The market size for third-party medical testing services in China was 630.5 billion yuan in 2022, with a significant drop expected in 2023 as pandemic testing demands decrease [6]. - The projected market size for 2024 is 388.8 billion yuan, with special testing accounting for 189.3 billion yuan and general testing for 199.5 billion yuan [6]. - By 2025, the market is expected to grow to approximately 444.9 billion yuan, with special testing at 218.1 billion yuan and general testing at 226.8 billion yuan [6]. Group 4: Industry Chain Structure - The third-party medical testing industry relies on specialized medical services, acting as a substitute for traditional hospital testing departments [8]. - The upstream of the industry includes suppliers of medical devices and testing reagents, while the downstream consists of various healthcare institutions that increasingly outsource testing services [8]. Group 5: Competitive Landscape - The market is characterized by a concentration of major players, with KingMed and Dian Diagnostics holding a combined market share of 36.16% [15]. - KingMed leads the market with a 17.04% share, providing services to over 20,000 medical institutions across 31 provinces and regions [15]. - Smaller third-party testing institutions face challenges due to limited scale and capabilities, leading to market exit pressures since 2015 [15]. Group 6: Financial Performance of Key Players - In 2024, KingMed reported revenues of 6.627 billion yuan, Dian Diagnostics 4.520 billion yuan, and Aidi Kang 2.914 billion yuan, among others [18]. Group 7: Development Trends - The third-party medical testing sector is becoming increasingly important, with regulatory changes posing new challenges [20]. - The industry is expected to focus on technological upgrades and strategic partnerships to enhance profitability and service quality [20]. - Automation, platformization, and intelligence are emerging as key trends in the development of third-party medical laboratories [20].

Group 1 - The controlling shareholder, Mr. Gao Yang, has faced forced execution of up to 3,535,214 shares of the company, representing no more than 1% of the total share capital, due to a default in a stock pledge repurchase business [1][2] - The forced execution period is from May 20, 2025, to June 9, 2025, with an execution average price of 13.10 yuan per share [2][3] - Prior to the forced execution, Mr. Gao held 31,988,723 shares (9.0486% of total share capital), which decreased to 28,453,510 shares (8.0486%) after the execution [3] Group 2 - The shares being executed were obtained through a major asset restructuring transaction involving the acquisition of 100% equity of Beijing Berry and Kang Biotechnology Co., Ltd. [2] - The forced execution does not violate any previously disclosed holding intentions or commitments by the controlling shareholder [3][4] - The combined shareholding of Mr. Gao and his concerted action partner, Ms. Hou Ying, decreased from 14.27% to 11.95% during the execution period [3]

成都市贝瑞和康基因技术股份有限公司 关于持股5%以上股东所持部分股份被司法强制执行实施结果的公告 控股股东高扬先生保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"或"贝瑞基因"）于 2025年5月17日披露了《关于持股5%以上股东所持部分股份被司法强制执行的提示性公 告》（公告编号：2025-025），公司控股股东高扬先生在国信证券股份有限公司（以 下简称"国信证券"）开展的股票质押回购业务发生违约，成渝金融法院裁定强制变 现被执行人高扬先生持有的"贝瑞基因"股票不超过3,535,214股（占公司总股本比例 不超过1%），强制执行截止日期为2025年7月10日（以下简称"本次强制执行"）。 近日，公司收到了控股股东高扬先生出具的《关于持股5%以上股东所持部分股份 被强制执行实施完成的告知函》，在本次强制执行期间，高扬先生累计被强制执行 3,535,213股公司股份，占公司总股本比例不超过1%。 一、强制执行情况 证券代码：000710 证券简称： ...

Core Viewpoint - The announcement reveals that the controlling shareholder of Berry Genomics, Mr. Gao Yang, has defaulted on a stock pledge repurchase agreement, leading to a court-ordered forced liquidation of his shares in the company [1] Group 1: Shareholder Actions - Mr. Gao Yang is subject to a court ruling that mandates the forced liquidation of up to 3.5352 million shares of Berry Genomics, which represents no more than 1% of the company's total share capital [1] - The forced execution deadline is set for July 10, 2025, indicating a timeline for the liquidation process [1] Group 2: Shareholding Changes - Following the forced execution, Mr. Gao Yang and his concerted party, Ms. Hou Ying, have seen their combined shareholding decrease from 11.99% to 11.95% of the total share capital, reflecting a change of 0.04% due to the forced execution [1] - The shares are to be executed at a price range of 12.59 to 14.84 yuan per share, which provides insight into the potential market impact of the forced sale [1]

3、公司目前生产经营情况正常，该事项未对公司正常经营活动产生重大 影响。 证券代码：000710 证券简称：贝瑞基因 公告编号：2025-032 成都市贝瑞和康基因技术股份有限公司 关于控股股东之一致行动人所持公司股份将被司法拍卖的 提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次拍卖标的物为公司控股股东之一致行动人侯颖女士持有的本公司 13,785,075 股股票，占其持有公司股份的比例为 100.00%，占公司总股本的 比例为 3.90%。上述将被司法拍卖的股份均为无限售流通股，均已被质押并分 别被司法再冻结和司法标记。 2、目前该拍卖事项尚在公示阶段，后续可能涉及竞拍、缴款、法院执行 法定程序、股权变更、过户等环节，存在一定的不确定性，公司将根据进展情 况，依法履行相应的信息披露义务。敬请广大投资者注意投资风险。 2、股东股份累计被司法拍卖的情况 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因"或"公司"） 于近日收到控股股东之一致行动人侯颖女士发送的《成渝金融法院网络司法 拍卖事项通知书》并通过司法拍卖网络平台查 ...

Group 1 - The company, Chengdu Berry Genomics Technology Co., Ltd., has agreed to provide a joint liability guarantee for its wholly-owned subsidiary, Beijing Berry Genomics Biotechnology Co., Ltd., which applied for a comprehensive credit line of 30 million yuan from the Bank of China [1] - The board of directors approved the guarantee without needing to submit it to the shareholders' meeting, as per relevant regulations [1] - The total amount of external guarantees provided by the company and its subsidiaries is 317 million yuan, accounting for 18.87% of the latest audited net assets [3][4] Group 2 - The subsidiary, Beijing Berry, has total assets of approximately 2.15 billion yuan and total liabilities of about 693.94 million yuan, resulting in net assets of approximately 1.45 billion yuan [2] - The subsidiary reported a total revenue of approximately 443.45 million yuan, with a net loss of about 29.26 million yuan [2] - The company has no overdue guarantees or litigation related to guarantees as of the announcement date [4]

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-031 成都市贝瑞和康基因技术股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保审批情况概述 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因""公司"） 于 2025 年 3 月 24 日召开第十届董事会第十二次会议审议通过了《关于为全资 子公司提供担保的议案》。公司之全资子公司北京贝瑞和康生物技术有限公司 （以下简称"北京贝瑞"）向中国民生银行股份有限公司北京分行（以下简称 "民生银行北京分行"）申请综合授信 10,000 万元，授信期限 1 年。公司拟为 北京贝瑞使用上述授信所形成的债务提供连带责任保证担保，北京贝瑞以取得 不动产权的位于昌平区生命园路 4 号院 5 号楼的房产为使用上述授信所形成的 债务提供抵押担保。具体内容详见公司于 2025 年 3 月 25 日在巨潮资讯网上披 露的《关于为全资子公司提供担保的公告》（公告编号：2025-007）。 近日，公司与民生银行北京分行签订了《最高额保证合同》，为北京贝瑞在 民生银行 ...